发明授权
- 专利标题： Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
-
申请号： US15736614申请日： 2015-10-22
-
公开(公告)号： US10775385B2公开(公告)日： 2020-09-15
- 发明人: James Philip O'Connell , John Robert Porter , Alastair Lawson , Boris Kroeplien , Stephen Edward Rapecki , Timothy John Norman , Graham John Warrellow , Tracy Lynn Arakaki , Alex Buntin Burgin , William Ross Pitt , Mark Daniel Calmiano , David Andreas Schubert , Daniel John Lightwood , Rebecca Jayne Wootton
- 申请人： UCB Biopharma SPRL
- 申请人地址： BE Brussels
- 专利权人： UCB BIOPHARMA SRL
- 当前专利权人： UCB BIOPHARMA SRL
- 当前专利权人地址： BE Brussels
- 代理机构： Medler Ferro Woodhouse & Mills PLLC
- 优先权： com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@447b52c
- 国际申请： PCT/EP2015/074491 WO 20151022
- 国际公布： WO2016/202412 WO 20161222
- 主分类号： G01N33/68
- IPC分类号： G01N33/68 ; C07K14/525 ; C07K14/705 ; C07K16/24 ; A61P37/00 ; C07D401/14 ; C07D471/00 ; C07D213/72 ; C07D235/04 ; C07D239/26 ; C07D471/04 ; A61K47/64 ; A61P35/00
摘要：
A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
公开/授权文献
- US20180231562A1 NOVEL TNFalpha STRUCTURE FOR USE IN THERAPY 公开/授权日：2018-08-16
信息查询
IPC分类:
